NXTC vs. RENB, KLRS, BLUE, ADVM, VRCA, DTIL, AADI, ATRA, RNXT, and VTVT
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Renovaro (RENB), Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), Precision BioSciences (DTIL), Aadi Bioscience (AADI), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.
NextCure vs. Its Competitors
NextCure (NASDAQ:NXTC) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.
Renovaro's return on equity of -60.38% beat NextCure's return on equity.
NextCure presently has a consensus price target of $3.50, indicating a potential upside of 668.22%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than Renovaro.
In the previous week, Renovaro had 1 more articles in the media than NextCure. MarketBeat recorded 2 mentions for Renovaro and 1 mentions for NextCure. Renovaro's average media sentiment score of 0.53 beat NextCure's score of 0.00 indicating that Renovaro is being referred to more favorably in the news media.
NextCure has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
42.7% of NextCure shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 13.3% of NextCure shares are held by insiders. Comparatively, 21.7% of Renovaro shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Renovaro is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
Summary
Renovaro beats NextCure on 7 of the 13 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NextCure Competitors List
Related Companies and Tools
This page (NASDAQ:NXTC) was last updated on 7/9/2025 by MarketBeat.com Staff
Free NXTC Stock Alerts